The results of the first phase of the vaccine developed in India against corona have been published in the famous medical journal The Lancet. According to the Journal, the vaccine has boosted the immune response in first-line trials with no serious side effects.
The newspaper reports that the number of problems with covisinin first includes injectable pain, then headache and fever, and fatigue. Susitra Allah, Joint Director of Bharat Biotech, is the first vaccine in India for cocaine in India, and its data is printed in The Lancet.
The Lancet study noted that “the BBV152 code-named vaccine is well tolerated in all dose groups. It also did not reveal any vaccine-related serious events.”
Biotech industry experts say every vaccine is a cause of pain and fever, but there is nothing that is completely safe and secure that requires a vaccine.
One of the most reprehensible things Kovacsin said was that when it submitted its application for emergency use approval, none of its data was public. After appearing on The Lancet, Suchitra Allah tweeted that “India’s invention has earned international recognition.”
Phase 2 similar peer review studies are still awaiting and phase 3 trials are underway, as the government continues to provide employment to millions of frontline employees. While the first two phases of vaccine trials usually focus on their safety, the third phase usually determines its effectiveness.
Explain that the vaccine developed in India was prepared by Bharat Biotech in collaboration with the Medical Council of India (ICMR) and the National Institute of Virology (NIV), Pune. Kovacsin has been approved by the Government of India this month for emergency use in clinical trial mode.
.
